Cargando…

A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma

Gene editing is a crucial and effective strategy to treat genetic diseases. Safe and effective delivery vectors are specially required for efficient gene editing in vivo of CRISPR/Cas9 system. Interestingly, lactose, a natural saccharide, can specifically bind to asialoglycoprotein receptors, highly...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Yu, Liu, Yanli, Yu, Bingran, Hu, Yang, Zhang, Nasha, Zheng, Yan, Yang, Ming, Xu, Fu‐Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507475/
https://www.ncbi.nlm.nih.gov/pubmed/32995132
http://dx.doi.org/10.1002/advs.202001424
_version_ 1783585234793529344
author Qi, Yu
Liu, Yanli
Yu, Bingran
Hu, Yang
Zhang, Nasha
Zheng, Yan
Yang, Ming
Xu, Fu‐Jian
author_facet Qi, Yu
Liu, Yanli
Yu, Bingran
Hu, Yang
Zhang, Nasha
Zheng, Yan
Yang, Ming
Xu, Fu‐Jian
author_sort Qi, Yu
collection PubMed
description Gene editing is a crucial and effective strategy to treat genetic diseases. Safe and effective delivery vectors are specially required for efficient gene editing in vivo of CRISPR/Cas9 system. Interestingly, lactose, a natural saccharide, can specifically bind to asialoglycoprotein receptors, highly expressed on the surface of hepatocellular carcinoma (HCC) cells. Herein, a lactose‐derived branched cationic biopolymer (LBP) with plentiful reducible disulfide linkages and hydroxyl groups is proposed as a potential delivery vector of CRISPR/Cas9 system for efficient genome editing in vivo to treat orthotopic HCC. LBP is synthesized via a facile one‐pot ring‐opening reaction. LBP possesses excellent compacting ability, degradability, biocompatibility, gene transfection performances, and HCC‐targeting ability. LBP‐mediated delivery of classical pCas9‐survivin, which can target and knockout survivin oncogene, produces efficient gene editing performances, and superb anti‐cancer activities in orthotopic HCC mouse models. This study provides an attractive and safe strategy for the rational design of CRISPR/Cas9 delivery system.
format Online
Article
Text
id pubmed-7507475
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-75074752020-09-28 A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma Qi, Yu Liu, Yanli Yu, Bingran Hu, Yang Zhang, Nasha Zheng, Yan Yang, Ming Xu, Fu‐Jian Adv Sci (Weinh) Full Papers Gene editing is a crucial and effective strategy to treat genetic diseases. Safe and effective delivery vectors are specially required for efficient gene editing in vivo of CRISPR/Cas9 system. Interestingly, lactose, a natural saccharide, can specifically bind to asialoglycoprotein receptors, highly expressed on the surface of hepatocellular carcinoma (HCC) cells. Herein, a lactose‐derived branched cationic biopolymer (LBP) with plentiful reducible disulfide linkages and hydroxyl groups is proposed as a potential delivery vector of CRISPR/Cas9 system for efficient genome editing in vivo to treat orthotopic HCC. LBP is synthesized via a facile one‐pot ring‐opening reaction. LBP possesses excellent compacting ability, degradability, biocompatibility, gene transfection performances, and HCC‐targeting ability. LBP‐mediated delivery of classical pCas9‐survivin, which can target and knockout survivin oncogene, produces efficient gene editing performances, and superb anti‐cancer activities in orthotopic HCC mouse models. This study provides an attractive and safe strategy for the rational design of CRISPR/Cas9 delivery system. John Wiley and Sons Inc. 2020-07-21 /pmc/articles/PMC7507475/ /pubmed/32995132 http://dx.doi.org/10.1002/advs.202001424 Text en © 2020 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Full Papers
Qi, Yu
Liu, Yanli
Yu, Bingran
Hu, Yang
Zhang, Nasha
Zheng, Yan
Yang, Ming
Xu, Fu‐Jian
A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma
title A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma
title_full A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma
title_fullStr A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma
title_full_unstemmed A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma
title_short A Lactose‐Derived CRISPR/Cas9 Delivery System for Efficient Genome Editing In Vivo to Treat Orthotopic Hepatocellular Carcinoma
title_sort lactose‐derived crispr/cas9 delivery system for efficient genome editing in vivo to treat orthotopic hepatocellular carcinoma
topic Full Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507475/
https://www.ncbi.nlm.nih.gov/pubmed/32995132
http://dx.doi.org/10.1002/advs.202001424
work_keys_str_mv AT qiyu alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT liuyanli alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT yubingran alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT huyang alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT zhangnasha alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT zhengyan alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT yangming alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT xufujian alactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT qiyu lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT liuyanli lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT yubingran lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT huyang lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT zhangnasha lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT zhengyan lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT yangming lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma
AT xufujian lactosederivedcrisprcas9deliverysystemforefficientgenomeeditinginvivototreatorthotopichepatocellularcarcinoma